The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Open accessAbstract
Disease overview: Chronic lymphocytic leukemia (CLL) is one of the most frequent types of leukemia. It typically occurs in elderly patients and has a highly variable clinical course. Leukemic transformation is initiated by specific genomic alterations that interfere with the regulation of proliferation and of apoptosis in clonal B‐cells. Diagnosis: The diagnosis is established by blood counts, blood smears, and immunophenotyping of circulating B‐lymphocytes, which identify a clonal B‐cell population carrying the CD5 antigen as well as typical B‐cell markers. Prognosis and staging: The clinical staging systems provide prognostic information by using the results of physical examination and blood counts. Various biological and genetic markers provide additional prognostic information. Deletions of the short arm of chromosome 17 (del[17p]) and/or mutations of the TP53 gene predict resistance to chemoimmunotherapy and a shorter time to progression with most targeted therapies. The CLL international prognostic index integrates genetic, biological, and clinical variables to identify distinct risk groups of patients with CLL. Therapy: Only patients with active or symptomatic disease or with advanced Binet or Rai stages require therapy. When treatment is indicated, several therapeutic options exist: a combination of the B‐cell lymphoma 2 (BCL2) inhibitor venetoclax with obinutuzumab, monotherapy with inhibitors of Bruton tyrosine kinase (BTK) such as ibrutinib and acalabrutinib, or chemoimmunotherapy. At relapse, the initial treatment may be repeated, if the treatment‐free interval exceeds 3 years. If the disease relapses earlier, therapy should be changed using an alternative regimen. Patients with a del(17p) or TP53 mutation are usually resistant to chemotherapy and should, therefore, be treated with targeted agents. Future challenges: Combinations of targeted agents are now being investigated to create efficient, potentially curative therapies of CLL with fixed duration. One of the most relevant questions currently addressed in clinical trials is the comparison of monotherapies with BTK inhibitors with fixed duration combination therapies. Moreover, the optimal sequencing of targeted therapies remains to be determined. Alternative therapies are needed for patients with BTK and BCL2 inhibitor double‐refractory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
Chanan-Khan, A. A., Zaritskey, A. Y., Egyed, M., Vokurka, S., Семочкин, С. В., Schuh, A., Kassis, J., Simpson, D., Zhang, J., Purse, B., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30168-0 · Cited by 39
Byrd, J. C., Hillmen, P., Ghia, P., Kater, A. P., Chanan-Khan, A. A., Furman, R. R., O'Brien, S. M., Yenerel, M. N., Illés, Á., Kay, N. E., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.7500 · Cited by 39
Cramer, P., von Tresckow, J., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A., Fischer, K., Wendtner, C., Kreuzer, K., Stilgenbauer, S., et al. (2018) · Future Oncology · doi:10.2217/fon-2017-0442 · Cited by 33
Self-citationSiddiqi, T., Soumerai, J. D., Dorritie, K. A., Stephens, D. M., Riedell, P. A., Arnason, J. E., Kipps, T. J., Gillenwater, H. H., Gong, L., Yang, L., et al. (2020) · Blood · doi:10.1182/blood-2020-140491 · Cited by 33
Rogers, K. A., Huang, Y., Dotson, E. K., Lundberg, J., Andritsos, L. A., Awan, F. T., Woyach, J. A., & Byrd, J. C. (2018) · British Journal of Haematology · doi:10.1111/bjh.15508 · Cited by 29
How I treat chronic lymphocytic leukemia after venetoclax
Lew, T. E., Tam, C. S. L., & Seymour, J. F. (2021) · Blood · doi:10.1182/blood.2020008502 · Cited by 26
Maurer, C., Pflug, N., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Groß-Ophoff-Müller, C., Langerbeins, P., Fink, A., Eichhorst, B. F., et al. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12714 · Cited by 20
Self-citationFürstenau, M., Fink, A. M., Schilhabel, A., Weiss, J. M., Robrecht, S., Eckert, R., de la Serna, J., Crespo, M., Coscia, M., Vitale, C., et al. (2020) · Blood · doi:10.1182/blood.2020008609 · Cited by 20
Self-citationOn the architecture of translational research designed to control chronic lymphocytic leukemia
Hallek, M. J. (2018) · Hematology · doi:10.1182/asheducation-2018.1.1 · Cited by 15
Self-citationQuinquenel, A., Fornecker, L., Letestu, R., Fleury, C., Ysebaert, L., Dilhuydy, M., Guièze, R., Feugier, P., Roos‐Weil, D., Willems, L., et al. (2018) · Blood · doi:10.1182/blood-2018-99-114027 · Cited by 8
Cited by
Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. D. O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01620-2 · Cited by 4,004
Consequences of genetic variants in miRNA genes
Machowska, M., Galka-Marciniak, P., & Kozlowski, P. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.11.036 · Cited by 40
Integrin Signaling Shaping BTK-Inhibitor Resistance
Polcik, L., Dannewitz Prosseda, S., Pozzo, F., Zucchetto, A., Gattei, V., & Hartmann, T. N. (2022) · Cells · doi:10.3390/cells11142235 · Cited by 15
Metadata
- Authors
- Hallek, M., & Al‐Sawaf, O.
- Venue
- American Journal of Hematology
- Publisher
- Wiley
- Published
- 2021-11-24
- Volume
- 96
- Issue
- 12
- Pages
- 1679-1705
- ISSN
- 0361-8609 (ISSN-L)
- 1096-8652
- OpenAlex
- W3204288598
- Cited by
- 393
- References
- 210
- FWCI
- 28.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.